Pembrolizumab (and friends) in pediatric malignancies: should we consider Hodgkin lymphoma a world of its own?

Detalles Bibliográficos
Autores principales: Algeri, Mattia, Locatelli, Franco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576004/
https://www.ncbi.nlm.nih.gov/pubmed/33145331
http://dx.doi.org/10.21037/atm.2020.04.54
_version_ 1783597924813373440
author Algeri, Mattia
Locatelli, Franco
author_facet Algeri, Mattia
Locatelli, Franco
author_sort Algeri, Mattia
collection PubMed
description
format Online
Article
Text
id pubmed-7576004
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-75760042020-11-02 Pembrolizumab (and friends) in pediatric malignancies: should we consider Hodgkin lymphoma a world of its own? Algeri, Mattia Locatelli, Franco Ann Transl Med Editorial Commentary AME Publishing Company 2020-09 /pmc/articles/PMC7576004/ /pubmed/33145331 http://dx.doi.org/10.21037/atm.2020.04.54 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Editorial Commentary
Algeri, Mattia
Locatelli, Franco
Pembrolizumab (and friends) in pediatric malignancies: should we consider Hodgkin lymphoma a world of its own?
title Pembrolizumab (and friends) in pediatric malignancies: should we consider Hodgkin lymphoma a world of its own?
title_full Pembrolizumab (and friends) in pediatric malignancies: should we consider Hodgkin lymphoma a world of its own?
title_fullStr Pembrolizumab (and friends) in pediatric malignancies: should we consider Hodgkin lymphoma a world of its own?
title_full_unstemmed Pembrolizumab (and friends) in pediatric malignancies: should we consider Hodgkin lymphoma a world of its own?
title_short Pembrolizumab (and friends) in pediatric malignancies: should we consider Hodgkin lymphoma a world of its own?
title_sort pembrolizumab (and friends) in pediatric malignancies: should we consider hodgkin lymphoma a world of its own?
topic Editorial Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576004/
https://www.ncbi.nlm.nih.gov/pubmed/33145331
http://dx.doi.org/10.21037/atm.2020.04.54
work_keys_str_mv AT algerimattia pembrolizumabandfriendsinpediatricmalignanciesshouldweconsiderhodgkinlymphomaaworldofitsown
AT locatellifranco pembrolizumabandfriendsinpediatricmalignanciesshouldweconsiderhodgkinlymphomaaworldofitsown

Ejemplares similares